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There are many potential mechanisms by which supplementation with the amino acid glutamine could prove beneficial in critical illness. Plasma glutamine levels fall in patients with critical illness and glutamine is released from muscle to be used by rapidly-dividing cells (such as the gut and immune system) and for renal acid-base homeostasis (1) . The fall in glutamine levels may suggest that glutamine becomes a 'conditionally essential' amino acid in critical illness. Glutamine supplementation improves N balance in parenteral nutrition support (2) . Glutamine is particularly important as a precursor of glutathione and thus in antioxidant defence.
Glutamine also plays a role in intracellular signalling, enhances heat-shock protein expression (3) , prevents apoptosis in injury and attenuates hyperinflammation (1) . There is some evidence to suggest that glutamine may reduce gut injury and inflammation in critical illness, thus influencing bacterial translocation across the gut wall (4) . Glutamine may also improve insulin sensitivity in critical illness (5) . With the ability now to provide glutamine in parenteral nutrition, as well as additional enteral supplements, randomised controlled trials have evaluated whether glutamine provides clinical benefits.
Guidelines for the use of glutamine in critical illness have recommended enteral glutamine for patients with burns or trauma and parenteral glutamine where parenteral nutrition is required (6) . However, not all guidelines for critical illness have supported the use of parenteral glutamine for all patients requiring parenteral nutrition and the quality of trials has been considered poor for guideline recommendations (7) . It has been shown that surgery causes some cytokine activation and some depression of cellular defences (8) , but the systemic inflammatory response of critical illness is best represented by hyperinflammation and marked cellular immune dysfunction at the same time. Thus, responses to glutamine supplementation may differ between patients undergoing surgery and critically-ill patients. The present systematic review examines the use of glutamine parenterally and enterally in critical illness and surgical groups of patients separately.
Methods
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Heterogeneity amongst trials was assessed by the I 2 statistic (11) , where ‡ 50 % was taken as indicating significant heterogeneity. Publication bias was examined by funnel plot analysis. Meta-analyses were undertaken using Review Manager version 4.2.7 software (Cochrane Collaboration, Oxford, UK). Risk ratios (RR), OR and 95% CI are reported.
Results
Data are presented from thirty-one randomised controlled trials that provided data . Twenty-two trials were identified in patients with critical illness (burns, two trials; mixed intensive care unit population, nine trials; patients with trauma, three trials; patients with pancreatitis, four trials; patients with surgical complications, four trials). Eight trials were in patients undergoing elective gastrointestinal surgery, for whom parenteral nutrition support post-operatively would not normally be provided. One trial Parenteral nutrition Estivariz et al. (16) Fuentes-Orozco et al. (18) Fuentes-Orozco et al. (17) Goeters et al. (20) Griffiths et al. (21) Sahin et al. (38) Wischmeyer et al. (42) Subtotal (95 % CI)
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evaluated glutamine-containing parenteral nutrition in a mixed hospital population cared for by the nutrition team (37) . Trial quality, as reported, was often limited, particularly in terms of reporting concealment of randomisation, intention-to-treat analysis and blinding of outcome assessment (although this factor is not likely to be a problem for reporting of deaths).
Mortality
Parenteral glutamine in critical illness was associated with a non-significant reduction in mortality (RR 0 . 71 (95 % CI 0 . 49, 1 . 03); P = 0 . 07; Fig. 1 ). For enteral glutamine in critical illness the RR was 1 . 05 (95 % CI 0 . 71, 1 . 54; P = 0 . 81). Two surgical trials reported mortality and one trial reported for a mixed hospital population, in neither case was there a significant reduction. Overall, if all population groups are combined the RR for mortality was 0 . 84 (95 % CI 0 . 66, 1 . 07; P = 0 . 17). Thus, there was a trend for a beneficial effect, most clearly for parenteral glutamine in critical illness.
Participants with infection
For enteral glutamine in critical illness the RR was 0 . 91 (95 % CI 0 . 74, 1 . 10; P = 0 . 33; Fig. 2 ). Parenteral glutamine in critical illness was associated with a significant reduction in infections (RR 0 . 78 (95% CI 0 . 63, 0 . 97); P = 0 . 03). In patients following surgery who were given parenteral nutrition containing glutamine, whether they required parenteral nutrition or not, there was a significant reduction in participants with infection (RR 0 . 43 (95% CI 0 . 27, 0 . 69); P< 0 . 001). Overall, for all patient groups there was a significant reduction in participants with infection (RR 0 . 81 (95 % CI 0 . 70, 0 . 93); P = 0 . 003).
For the outcome of participants with infection, which provided the most data, a funnel plot examining for suggestion of publication bias was undertaken (Fig. 3) . The individual data points should be evenly distributed in an inverted 'V' on either side of the vertical axis. The plot shows fewer data points to the top right of the line, suggesting that small trials with negative results, not in favour of glutamine, were less likely to be published.
Participants with multi-organ or renal failure
Few trials reported multi-organ or renal failure. Combining all parenteral glutamine trials there was a significant reduction (RR 0 . 60 (95 % CI 0 . 42, 0 . 85); P = 0 . 004; Fig. 4 ), but not for enteral glutamine (RR 1 . 15 (95 % CI 0 . 70, 1 . 87); P = 0 . 59). Overall, there was no suggestion that glutamine was harmful in terms of multi-organ or renal failure (RR 0 . 75 (95 % CI 0 . 56, 0 . 99); P = 0 . 04). (17) Ockenga et al. (33) Sahin et al· (38) Total ( 
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Participants with pancreatitis
Parenteral glutamine was associated with a significant reduction in mortality (RR 0 . 36 (95 % CI 0 . 13, 0 . 99); P = 0 . 05; Fig. 5 ) and a non-significant reduction in infection (RR 0 . 49 (95% CI 0 . 20, 1 . 16); P = 0 . 10; Fig. 6 ) in participants with pancreatitis.
Examination of dose effects in parenteral and enteral glutamine-supplemented critical illness
For trials providing ‡ 4 . 2 g glutamine/kg body weight as the total dose over time the OR for mortality was 0 . 66 (95 % CI 0 . 43, 1 . 01; P = 0 . 06) and for doses < 4 . 2 g glutamine/kg body weight OR was 0 . 91 (95% CI 0 . 66, 1 . 27; P = 0 . 59; Fig. 7 ). These findings suggest that higher doses may be more effective, but there was no significant difference between the subgroups in the interaction test (P = 0 . 27). However, the trials with the higher dose of glutamine showed high heterogeneity (I 2 57 %).
Conclusions
Compared with a systematic review conducted 3 years previously (43) there have been some changes to the results for the outcomes. The effect of glutamine on mortality is very similar to that reported previously, with an RR of 0 . 71 (95 % CI 0 . 49, 1 . 03) for parenteral glutamine. Although this result is not significant, the confidence intervals do not exclude the possibility of benefit on mortality.
The data now appear to suggest that parenteral glutamine reduces infections in critical illness, but the evidence for enteral glutamine in critical illness is less strong. This finding is the reverse of the results from the previous review. The possibility of publication bias for this outcome remains a concern. The methodological quality of nutrition-support trials in critical illness, particularly in relation to intention-to-treat analysis, concealment of allocation and blinding of outcome assessment, also requires improvement (44) .
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Large multicentre randomised trials, with rigorous methodology, are underway to examine the role of glutamine in critical illness (45, 46) . The REDOXS g trial is recruiting 1200 patients in North America and Europe with organ dysfunction in critical illness (47) . Participants are randomised to 0 . 35 g glutamine/kg body weight per d administered parenterally (independent of the need for parenteral nutrition) and 30 g glutamine/d administered enterally and/or parenteral and enteral antioxidants or no supplements in a factorial design. The main outcome of the trial is 28 d mortality; survival to 6 months and infections are also outcomes. The relatively high doses of glutamine and antioxidants have been established on the basis of reduction in markers of oxidative stress and greater preservation of glutathione without affecting organ function (46) . The Scottish Intensive care Glutamine or seleNium Evaluative Trial is examining parenteral nutrition with 20 . 2 g glutamine with or without 500 mg parenteral Se/d, also in a factorial design with isonitrogenous and isoenergetic regimens, in 500 patients who require parenteral feeding in intensive care (45) . There is no suggestion from the data in the present review that parenteral or enteral glutamine is harmful and the meta-analysis suggests that parenteral glutamine may reduce organ failure; however, few trials reported details of organ failure.
Three small trials suggest that glutamine may reduce mortality in acute pancreatitis. However, only a total of 112 patients were enrolled in these trials and not all trials had patients with severe pancreatitis (33) . It is not clear whether enteral nutrition support could have been achieved in these patients (48) . There is some suggestion that higher doses (equivalent to ‡ 0 . 42 g glutamine/kg body weight for 10 d) may have more effect on mortality.
Two recent Cochrane reviews (49, 50) have also examined the use of parenteral or enteral glutamine in children. One review has found insufficient evidence to support the use of parenteral or enteral glutamine in preterm infants to prevent morbidity and mortality (49) . The other review comes to the same conclusion for parenteral and enteral glutamine use in young infants with severe gastrointestinal disease (50) .
